Won Jin Park

Title: Innovations of Won Jin Park in Angiogenesis Inhibition

Introduction

Won Jin Park is a notable inventor based in Gyeonggi-do, South Korea. He has contributed significantly to the field of biochemistry and medical therapies, holding three patents focused on angiogenesis inhibition. His work has important implications for the treatment of various cancers and diseases related to abnormal blood vessel growth.

Latest Patents

Among his recent innovations, Park has developed improved peptides described in his patent titled "Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related diseases comprising same as active ingredient." This patent reveals two novel peptides: Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), that effectively inhibit angiogenesis. The first peptide features an acetylated L-Arg at the N-terminal position, while the second substitutes L-Arg with D-Arg. The compositions he designed aim to treat diseases like cancer, diabetic retinopathy, and senile macular degeneration, which are exacerbated by excessive angiogenesis. These peptides demonstrate a long half-life and show exceptional efficacy in countering VEGF-induced angiogenesis.

Career Highlights

Throughout his career, Won Jin Park has worked with esteemed organizations such as Avixgen Inc. and the Samsung Life Public Welfare Foundation. His contributions within these companies have advanced research in therapeutic applications for angiogenesis-related illnesses.

Collaborations

Park has collaborated with various talented professionals during his career, including Young Myeong Kim and Yi Yong Baek. These partnerships have fostered a collaborative environment for innovation and development in the pharmaceutical realm.

Conclusion

Won Jin Park stands out as an inventor whose work in peptide technology addresses critical health challenges related to angiogenesis. His innovative approaches and patented discoveries lay the groundwork for future advancements in medical treatments for cancer and other related diseases. As a dedicated researcher, he continues to contribute to the field, bringing hope to many affected by these conditions.